↓ Skip to main content

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Overview of attention for article published in Cardiovascular Diabetology, February 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#22 of 1,263)
  • High Attention Score compared to outputs of the same age (94th percentile)

Mentioned by

news
1 news outlet
twitter
72 tweeters

Citations

dimensions_citation
69 Dimensions

Readers on

mendeley
134 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Published in
Cardiovascular Diabetology, February 2019
DOI 10.1186/s12933-019-0828-y
Pubmed ID
Authors

Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari

Twitter Demographics

The data shown below were collected from the profiles of 72 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 134 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 134 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 20 15%
Researcher 18 13%
Student > Ph. D. Student 17 13%
Student > Master 13 10%
Other 9 7%
Other 27 20%
Unknown 30 22%
Readers by discipline Count As %
Medicine and Dentistry 45 34%
Pharmacology, Toxicology and Pharmaceutical Science 20 15%
Biochemistry, Genetics and Molecular Biology 10 7%
Agricultural and Biological Sciences 6 4%
Chemistry 5 4%
Other 13 10%
Unknown 35 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 52. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2022.
All research outputs
#639,343
of 21,682,700 outputs
Outputs from Cardiovascular Diabetology
#22
of 1,263 outputs
Outputs of similar age
#15,116
of 285,771 outputs
Outputs of similar age from Cardiovascular Diabetology
#1
of 1 outputs
Altmetric has tracked 21,682,700 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,263 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,771 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them